董事会认为，本公司获纳入恒生综合指数成份股，反映资本市场对本公司业务表现及增长前景的认同。 董事会相信，此次纳入将有助于扩大本公司股东基础，提升H股的交易流通性，并进一步增强本公司的 声誉及品牌知名度。 智通财经APP讯，中慧生物-B(02627)发布公告，本公司H股已获选定并将纳入恒生综合指数成份股，自 2026年3月9日起生效。恒生综合指数作为全面的H股指标，涵盖在香港交易所主板上市的累计市值最高 95%的公司，并获指数基金、互惠基金及业绩评估系统的广泛应用。 ...

董事会认为，公司获纳入恒生综合指数成份股，反映资本市场对公司业务表现及增长前景的认同。董事 会相信，此次纳入将有助于扩大公司股东基础，提升H股的交易流通性，并进一步增强公司的声誉及品 牌知名度。 格隆汇2月16日丨中慧生物-B(02627.HK)发布公告，公司H股已获选定并将纳入恒生综合指数成份股， 自2026年3月9日起生效。恒生综合指数作为全面的H股指标，涵盖在香港交易所主板上市的累计市值最 高95%的公司，并获指数基金、互惠基金及业绩评估系统的广泛应用。 ...

（於中華人民共和國成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Ab&B Bio-Tech CO., LTD. JS 江蘇中慧元通生物科技股份有限公司 董事會認為，本公司獲納入恒生綜合指數成份股，反映資本市場對本公司業務表 現及增長前景的認同。董事會相信，此次納入將有助於擴大本公司股東基礎，提 升H股的交易流通性，並進一步增強本公司的聲譽及品牌知名度。 關於中慧生物 我們是一家總部位於中國的疫苗公司，致力於創新疫苗及採用新技術方法的傳統 疫苗的研發、製造及商業化。我們密切追蹤傳染病的全球發病及疫苗研發的趨勢 來確定我們的產品管線，並專注於優質疫苗，以在中國取代傳統疫苗和進口疫 苗，並將我們的競爭優勢擴展至國際市場。我們的產品包括但不限於，四價流感 病毒亞單位疫苗，三價流感病毒亞單位疫苗及在研凍乾人用狂犬病疫苗，以及其 他在研疫苗。 承董事會命 江蘇中慧元通生物科技股份有限公司 執行董事、董事長兼總經理 安有才先生 香港，202 ...

截至该公告日期，该款疫苗成为中国首款且唯一一款获批上市的全人群全剂量三价流感病毒亚单位疫 苗。该产品在传统病毒裂解疫苗的基础上进行重大升级，具有保护全面、组分抗原纯度高、不良反应风 险低等优势。 2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中中慧生物- B(02627)获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一) 起生效，届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，中慧生物-B有可能被调入港 股通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 中慧生物-B(02627)发布公告，中国国家药品监督管理局已批准本集团针对所有年龄组别的三价流感病 毒亚单位疫苗的新药申请。 ...

经济观察网中慧生物-B(02627.HK)在近7天(2026年2月9日至13日)股价表现强势，呈现连续上涨态势。 截至2月13日收盘，股价报51.50港元，单日涨幅0.39%，近5日累计涨幅达10.33%，区间振幅为12.47%。 资金动向 资金面上，主力资金持续净流入，2月13日单日主力净流入350.60万港元，近5日主力净流入合计约 917.36万港元，显示机构资金关注度较高。 板块变化情况 板块对比方面，同期港股生物技术板块下跌0.95%，恒生指数下跌1.72%，公司股价逆势走强，凸显相 对韧性。 以上内容基于公开资料整理，不构成投资建议。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 江蘇中慧元通生物科技股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02627 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 296,361,845 RMB | | | 1 RMB | | 296,361,845 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 296,361,845 RMB | | | 1 RMB | | 296,361,845 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類 ...

Market Performance - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 2.23% to 26,775.57 points, and the Hang Seng Tech Index dropping by 3.36% to 5,526.31 points [1] - Major technology stocks saw significant losses, including Alibaba down 3.49%, Tencent down 1.24%, and JD.com down 1.69% [1] - Gold and silver prices fell sharply, with Shandong Gold and Chifeng Gold both dropping over 12% [1] Company Earnings Forecasts - Haiprime (09989.HK) expects a net profit of 284 million to 377 million yuan for 2025, a decrease of 41.71% to 56.09% year-on-year [2] - Datang Power (00991.HK) anticipates a net profit of approximately 6.8 billion to 7.8 billion yuan for 2025, an increase of about 51% to 73% year-on-year [6] - Longhua Automobile (02333.HK) projects total revenue of 222.79 billion yuan for 2025, a year-on-year growth of 10.19% [4] - CICC (03908.HK) forecasts a net profit of 8.542 billion to 10.535 billion yuan for 2025, an increase of 50% to 85% year-on-year [5] Company Warnings - Kaisa New Energy (01108.HK) issued a profit warning, expecting a net loss increase of approximately 90.07 million to 290 million yuan for 2025 [7] - Xinyi Alloy (00505.HK) also issued a profit warning, anticipating a 50% decrease in profit attributable to equity shareholders for 2025 [8] - Fudan Zhangjiang (01349.HK) expects a net loss of approximately 120 million to 180 million yuan for 2025 [9] Strategic Developments - Innovation Intelligence (02121.HK) signed a strategic cooperation agreement with Shanghai Jiao Tong University Hainan Research Institute [11] - Zhonghui Biotech-B (02627.HK) received approval from the National Medical Products Administration for its trivalent influenza virus subunit vaccine [12]

Major Events - Lanke Technology (06809) will conduct an IPO from January 30 to February 4, with an expected listing on February 9 [1] - Aixin Yuanzhi (00600) will conduct an IPO from January 30 to February 5, with an expected listing on February 10 [1] - Lexin Outdoor (02720) will conduct an IPO from January 31 to February 5, raising HKD 130 million from Horizon Capital and Huangshan Dejun [1] - Dongpeng Beverage (09980) sets the offer price at HKD 248 per share [1] - Zhonghui Biotech-B (02627) received approval from the National Medical Products Administration for a trivalent influenza virus subunit vaccine [1] - Kangzheng Pharmaceutical (00867) received approval for the first and only targeted drug for vitiligo treatment in China [1] - Shishi Pharmaceutical Group (02005) received production registration for Propafenone Hydrochloride Injection from the National Medical Products Administration [1] - China Aluminum (02600) plans to jointly acquire 68.6% of Brazilian Aluminum from Rio Tinto and will initiate a mandatory offer [1] - Yanzhou Coal Mining (01171) plans to transfer 100% equity of Inner Mongolia Xintai Coal [1] - Botai Car Union (02889) plans to collaborate with Ping An Property & Casualty to reconstruct the smart travel insurance ecosystem [1] - Jin Jing New Energy (01783) signed a strategic framework agreement with Tianqi Grand for lithium battery recycling and precious metal extraction [1] - Guangdong-Hong Kong-Macau Holdings (01396) subsidiary Hongce Data introduces Fudian Capital as a strategic investor for 40% equity [1] - China Mobile (00941), China Unicom (00762), and China Telecom (00728) will adjust the applicable scope of value-added tax for telecom services [1] Operating Performance - BYD Company (01211) sold approximately 210,000 new energy vehicles in January [2] - Geely Automobile (00175) reported total vehicle sales of 270,200 units in January, a year-on-year increase of about 1% [2] - Chery Automobile (09973) saw total sales of 191,500 vehicles in January, a year-on-year decrease of about 10.7% [2] - Seres (09927) reported total vehicle sales of 45,900 units in January, a year-on-year increase of 104.85% [2] - Great Wall Motors (02333) sold approximately 90,300 vehicles in January, a year-on-year increase of 11.59% [2] - Li Auto-W (02015) delivered 27,668 new vehicles in January, a year-on-year decrease of 7.5% [2] - NIO-SW (09866) delivered 27,182 vehicles in January, a year-on-year increase of 96.1% [2] - GAC Group (02238) reported vehicle sales of 116,600 units in January, a year-on-year increase of 18.47% [2] - Great Wall Motors (02333) released a preliminary report indicating a net profit attributable to shareholders of 9.912 billion yuan for 2025, a year-on-year decrease of 21.71% [2] - Shandong Gold (01787) expects a net profit attributable to shareholders of approximately 4.6 billion to 4.9 billion yuan for 2025, a year-on-year increase of 56% to 66% [2] Earnings Forecast - SF Express (09699) expects a year-on-year profit increase of no less than 80% for 2025 [3] - China International Capital Corporation (03908) anticipates a net profit attributable to shareholders of 8.542 billion to 10.535 billion yuan for 2025, a year-on-year increase of 50% to 85% [3] - China Shenhua (01088) expects a year-on-year decline in net profit for 2025 [3] - Datang Power (00991) anticipates a net profit of approximately 6.8 billion to 7.8 billion yuan for 2025, a year-on-year increase of about 51% to 73% [3] - China Southern Airlines (01055) expects a net profit attributable to shareholders of 800 million to 1 billion yuan for 2025, turning a profit [3] - Air China (00753) warns of a net loss attributable to shareholders of approximately 1.3 billion to 1.9 billion yuan for 2025 [3] - China Eastern Airlines (00670) warns of a net loss attributable to shareholders of approximately 1.3 billion to 1.8 billion yuan for 2025 [3] - GAC Group (02238) expects a net loss attributable to shareholders of 8 billion to 9 billion yuan for 2025 [3] - Ansteel (00347) warns of a net loss attributable to shareholders of approximately 4.077 billion yuan for 2025, a year-on-year narrowing of 42.75% [3] - Junshi Biosciences (01877) warns of a net loss attributable to shareholders of approximately 873 million yuan for 2025, a year-on-year decrease of about 31.85% [3]

Company News - Great Wall Motors (02333.HK) expects a total revenue of RMB 222.79 billion in 2025, representing a year-on-year increase of 10.19%. However, net profit is projected to decline by 21.71% to RMB 9.912 billion due to increased investments in new user channels and marketing for new models and technologies [2] - China Southern Airlines (01055.HK) anticipates turning a profit in 2025, with net profit expected to be between RMB 800 million and RMB 1 billion [2] - CICC (03908.HK) forecasts a net profit of RMB 8.542 billion to RMB 10.535 billion in 2025, reflecting a year-on-year increase of 50% to 85% [3] - Datang Power (00991.HK) projects a net profit of approximately RMB 6.8 billion to RMB 7.8 billion in 2025, indicating a year-on-year increase of about 51% to 73% [4] - Rongchang Bio (09995.HK) expects 2025 revenue of approximately RMB 3.25 billion, a year-on-year increase of about 89%, and a net profit of around RMB 716 million, achieving profitability [4] - Haijia Medical (06078.HK) anticipates revenue of approximately RMB 4.0 billion to RMB 4.05 billion in 2025, a year-on-year decrease of about 9% to 10%, with net profit expected to decline by 66% to 76% to around RMB 140 million to RMB 200 million [4] - Junshi Biosciences (01877.HK) expects 2025 revenue of around RMB 2.5 billion, a year-on-year increase of approximately 28.32%, with a net loss of about RMB 873 million, a reduction of 31.85% compared to the previous year [4] - Kaisa New Energy (01108.HK) issued a profit warning, expecting a year-on-year increase in net loss of approximately RMB 90.07 million to RMB 290 million [4] - Xingye Alloy (00505.HK) issued a profit warning, anticipating a year-on-year decrease in profit attributable to equity shareholders of about 50% [4] - Fudan Zhangjiang (01349.HK) issued a profit warning, expecting a net loss of approximately RMB 120 million to RMB 180 million in 2025 [4] - Chenming Paper (01812.HK) issued a profit warning, expecting a net loss of RMB 8.2 billion to RMB 8.8 billion, a significant increase compared to the previous year [5] - Tianqi Lithium (09696.HK) has commenced production of the first batch of standard chemical-grade lithium concentrate products from its third-phase expansion project [6] Financing and Buyback Activities - Xiaomi Group-W (01810.HK) repurchased approximately 4.2 million shares for about HKD 150 million, with repurchase prices ranging from HKD 35.13 to HKD 42.50 [10] - Vitasoy International (00345.HK) repurchased shares worth HKD 24.37 million, acquiring 3.492 million shares at prices between HKD 6.9 and HKD 7 [11] - Yujian Xiaomian (02408.HK) plans to repurchase up to HKD 100 million of H-shares [12] - Nanshan Aluminum International (02610.HK) completed a placement of 31 million shares, raising approximately HKD 1.987 billion [12]

Core Viewpoint - Zhonghui Biotech-B (02627) has achieved a significant milestone with the approval of China's first and only trivalent subunit influenza virus vaccine for the entire population, enhancing its product matrix in the subunit influenza vaccine sector [1][4]. Group 1: Product Development and Market Position - The company previously launched the first and only quadrivalent subunit influenza vaccine (Hui Er Kang Xin) for the entire population, establishing a comprehensive product matrix that meets diverse public health needs and market preferences [4]. - The successful approval of the trivalent vaccine is expected to drive the company's performance and value reassessment, as it aligns with the growing demand for influenza vaccination in China, where the vaccination rate is significantly lower than in the U.S. [5][6]. - The trivalent subunit vaccine is designed to have high antigen purity and fewer adverse reactions, making it particularly suitable for vulnerable populations such as children and the elderly [6]. Group 2: Financial Performance and Market Dynamics - Following the commercialization of the quadrivalent vaccine, the company has seen rapid revenue growth, with projected revenues increasing from 52.168 million yuan in 2023 to 260 million yuan in 2024, and a staggering 918.91% year-on-year growth in the first half of 2025 [7]. - The quadrivalent vaccine has achieved a 100% approval rate for product batch issuance and has expanded its sales network to over 1,100 disease control centers across 30 provinces in China [7]. - The company has also made progress in market access, with the quadrivalent vaccine passing preliminary review for inclusion in the 2025 National Commercial Health Insurance innovative drug list, which is expected to alleviate market promotion pressures [7]. Group 3: Future Growth and R&D Pipeline - The company is actively expanding its product offerings, including a clinical trial for an adjuvanted vaccine targeting individuals aged 65 and older, and research for a vaccine specifically for pregnant women, which could fill a current gap in immunization for infants aged 0-6 months [8]. - The company has a robust R&D pipeline, with multiple promising products under development, including a freeze-dried rabies vaccine and other vaccines targeting pneumonia and shingles, ensuring long-term sustainable growth [9][10]. - The company is also expanding its international market presence, with plans to enter markets in Canada, Singapore, Mexico, and Hong Kong by 2026, leveraging the seasonal differences in influenza activity across regions [11]. Group 4: Market Outlook and Investment Potential - Analysts predict that the company will achieve profitability by 2027, with projected revenues of 798 million yuan and 1.24 billion yuan in 2026 and 2027, respectively, indicating a clear growth trajectory [11]. - The successful approval of the trivalent influenza vaccine is expected to provide immediate revenue growth and enhance the company's competitive advantage in the high-potential subunit vaccine sector [11].